Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (671-680 of 754) with videos related to

Pageof 76
Sort By:
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
JAMA|September 1, 2004
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJames A de Lemos, Michael A Blazing, Stephen D Wiviott, et al.
Journal of the American College of Cardiology|August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEFJonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|April 13, 2011
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trialAndrew G Bostom, Myra A Carpenter, John W Kusek, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 16, 2023
Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical TrialMichael A Pfeffer, Tia C L Kohs, Helen H Vu, et al.
Journal of the American College of Cardiology|May 24, 2023
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection FractionRiccardo M Inciardi, Martin Abanda, Amil M Shah, et al.
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
Kidney International. Supplement|October 16, 2004
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuriaNagesh S Anavekar, Daniel J Gans, Tomas Berl, et al.
Pageof 76

Showing results (671-680 of 754) with videos related to

Sort By:
Pageof 76
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
JAMA|September 1, 2004
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJames A de Lemos, Michael A Blazing, Stephen D Wiviott, et al.
Journal of the American College of Cardiology|August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEFJonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|April 13, 2011
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trialAndrew G Bostom, Myra A Carpenter, John W Kusek, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 16, 2023
Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical TrialMichael A Pfeffer, Tia C L Kohs, Helen H Vu, et al.
Journal of the American College of Cardiology|May 24, 2023
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection FractionRiccardo M Inciardi, Martin Abanda, Amil M Shah, et al.
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
Kidney International. Supplement|October 16, 2004
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuriaNagesh S Anavekar, Daniel J Gans, Tomas Berl, et al.
Pageof 76